Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma
Authors:
Open Access
- 31 March 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (22) , 35639-35655
Abstract
Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastomaKeywords
This publication has 52 references indexed in Scilit:
- Modulation of Immunity by Antiangiogenic Molecules in CancerJournal of Immunology Research, 2012
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not AnticipateCancer Cell, 2012
- Cord Blood Stem Cells Inhibit Epidermal Growth Factor Receptor Translocation to Mitochondria in GlioblastomaPLOS ONE, 2012
- Regulation of Glioblastoma Progression by Cord Blood Stem Cells Is Mediated by Downregulation of Cyclin D1PLOS ONE, 2011
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastomaNeuro-Oncology, 2010
- Acquisition of Temozolomide Chemoresistance in Gliomas Leads to Remodeling of Mitochondrial Electron Transport ChainJournal of Biological Chemistry, 2010
- O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patientsNeuro-Oncology, 2009
- EGFRvIII‐Targeted Vaccination Therapy of Malignant GliomaBrain Pathology, 2009
- Distinct Structural Mechanisms for Inhibition of Pyruvate Dehydrogenase Kinase Isoforms by AZD7545, Dichloroacetate, and RadicicolStructure, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005